Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Decreased by Prudential Financial Inc.

Prudential Financial Inc. lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 12.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 181,129 shares of the company’s stock after selling 24,663 shares during the quarter. Prudential Financial Inc.’s holdings in Moderna were worth $7,755,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. State Street Corp lifted its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Moderna by 9.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock valued at $97,472,000 after purchasing an additional 211,426 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $31.12 on Friday. The firm has a fifty day moving average price of $34.72 and a 200-day moving average price of $44.38. The stock has a market cap of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47.

Analyst Ratings Changes

Several brokerages have commented on MRNA. UBS Group cut their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Berenberg Bank increased their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.